Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-2361
¥ million (operating loss)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 August 2025 to 31 January 2026ConsolidatedJapanese GAAPNet Sales32,441¥ millionYear on year +8.7%Progress 48.4%
Operating profit-2,361¥ million
Ordinary income-2,437¥ million
Net income attributable to owners of the parent-1,824¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share△63.09円
Financial position at period-end
Total assets32,255¥ million
of which net assets 9,771 ¥ millionEquity ratio 30.3%vs. prior year-end -5.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-2,782
Investment-538
Financials+1,854
Net change-1,466
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥7,586 million
Segment revenue
B2B Business3,57611.0%-4.9%
B2C Business28,73088.6%+10.7%
Biomedical business1040.3%-23.1%
Other300.1%
Segment profit
B2B Business502-29.1%
B2C Business-1,557
Biomedical business-260
Other-11
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥67,000 million (YoY +2.7%)
Operating profit¥2,000 million (YoY -15.5%)
Ordinary income¥2,000 million (YoY -21.7%)
Profit attributable to owners of the parent¥1,500 million (YoY +307.6%)
Revision to Earnings ForecastNet Sales Not disclosed → ¥67,000 million / Operating profit Not disclosed → ¥2,000 million / Ordinary income Not disclosed → ¥2,000 million / Profit attributable to owners of the parent Not disclosed → ¥1,500 million
Annual Dividend Forecast¥25 → ¥25（0.0%）
Factors Behind Changes in Business Performance
新製品の販売伸長やニューモシリーズ等の売上増により売上高は増加した一方、新製品育成のため広告宣伝を強化した結果、広告宣伝費が前年同期比23.0％増加し、営業損失となった。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥4 million / Extraordinary loss Loss on sale of shares of subsidiaries and affiliates ¥117 million
Depreciation and amortization¥327 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Not disclosed
Issued Shares at Period-End29,079,000株
Treasury Shares at Period-End35,623株
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 August 2025 to 31 January 2026 |
| Net Sales | ¥32,441 million (YoY +8.7%) |
| Operating profit | ¥-2,361 million |
| Ordinary income | ¥-2,437 million |
| Profit attributable to owners of the parent | ¥-1,824 million |
| Net income per share | △63.09円 |
| Equity ratio | End of the current fiscal period 30.3 / End of previous period 35.4 |
| Total assets | ¥32,255 million |
| Net assets | ¥9,771 million |
| Cash flows from operating activities | ¥-2,782 million |
| Cash flows from investing activities | ¥-538 million |
| Cash flows from financing activities | ¥1,854 million |
| Cash and cash equivalents at end of period | ¥7,586 million |
| Full-year earnings forecast | Net Sales ¥67,000 million (YoY +2.7%) / Operating profit ¥2,000 million (YoY -15.5%) / Ordinary income ¥2,000 million (YoY -21.7%) / Profit attributable to owners of the parent ¥1,500 million (YoY +307.6%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥67,000 million / Operating profit Not disclosed → ¥2,000 million / Ordinary income Not disclosed → ¥2,000 million / Profit attributable to owners of the parent Not disclosed → ¥1,500 million |
| Annual Dividend Forecast | ¥25 → ¥25（0.0%） |
| Segment revenue | B2B Business ¥3,576 million (YoY -4.9%) / B2C Business ¥28,730 million (YoY +10.7%) / Biomedical business ¥104 million (YoY -23.1%) / Other ¥30 million |
| Segment profit | B2B Business ¥502 million (YoY -29.1%) / B2C Business ¥-1,557 million / Biomedical business ¥-260 million / Other ¥-11 million |
| Depreciation and amortization | ¥327 million |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥4 million / Extraordinary loss Loss on sale of shares of subsidiaries and affiliates ¥117 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 29,079,000株 |
| Treasury Shares at Period-End | 35,623株 |
| Factors Behind Changes in Business Performance | 新製品の販売伸長やニューモシリーズ等の売上増により売上高は増加した一方、新製品育成のため広告宣伝を強化した結果、広告宣伝費が前年同期比23.0％増加し、営業損失となった。 |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.新製品育成のため広告宣伝を強化し、研究開発投資、新製品開発、販売チャネルの開拓に注力した。主力のニューモシリーズや新製品の売上は伸長した一方、広告宣伝費は前年同期比23.0％増の21,461百万円となった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.